Kieran Gallahue - Feb 8, 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Feb 8, 2022
Transactions value $
-$2,854,630
Form type
4
Date filed
2/8/2022, 07:19 PM
Previous filing
Jun 15, 2021
Next filing
Mar 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $719K +32.3K +939.59% $22.29 35.7K Feb 8, 2022 Direct
transaction EW Common Stock Sale -$3.57M -32.3K -90.38% $110.79 3.43K Feb 8, 2022 Direct F1
holding EW Common Stock 56.8K Feb 8, 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Director Stock Option (Right to Acquire) Options Exercise $0 -32.3K -100% $0.00* 0 Feb 8, 2022 Common Stock 32.3K $22.29 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $110.50 to $111.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

On May 29, 2020, the common stock of the Issuer split 3-for-1, resulting in the Reporting Person's ownership of additional shares of common stock and stock options. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.